MA47418A - Composés et compositions pour le traitement de troubles ophtalmiques - Google Patents

Composés et compositions pour le traitement de troubles ophtalmiques

Info

Publication number
MA47418A
MA47418A MA047418A MA47418A MA47418A MA 47418 A MA47418 A MA 47418A MA 047418 A MA047418 A MA 047418A MA 47418 A MA47418 A MA 47418A MA 47418 A MA47418 A MA 47418A
Authority
MA
Morocco
Prior art keywords
compositions
compounds
treatment
ophthalmic disorders
ophthalmic
Prior art date
Application number
MA047418A
Other languages
English (en)
Inventor
Jinquan Dong
Anneli Savinainen
Mohannad Shawer
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA47418A publication Critical patent/MA47418A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA047418A 2017-02-01 2018-02-01 Composés et compositions pour le traitement de troubles ophtalmiques MA47418A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762453153P 2017-02-01 2017-02-01

Publications (1)

Publication Number Publication Date
MA47418A true MA47418A (fr) 2021-06-02

Family

ID=61193197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047418A MA47418A (fr) 2017-02-01 2018-02-01 Composés et compositions pour le traitement de troubles ophtalmiques

Country Status (5)

Country Link
US (1) US20180215788A1 (fr)
EP (1) EP3576770A1 (fr)
JP (1) JP2020505476A (fr)
MA (1) MA47418A (fr)
WO (1) WO2018144742A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040213782A1 (en) * 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
RU2557290C2 (ru) 2009-09-25 2015-07-20 Шайр Орфан Терапис ГмбХ Новые агонисты npr-b
WO2011075471A2 (fr) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Nouveaux agonistes du npr-b et méthodes d'utilisation pour le traitement des troubles médiés par le peptide natriurétique de type c

Also Published As

Publication number Publication date
EP3576770A1 (fr) 2019-12-11
WO2018144742A1 (fr) 2018-08-09
US20180215788A1 (en) 2018-08-02
JP2020505476A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3463315A4 (fr) Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3723768A4 (fr) Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
MA51738A (fr) Composés pour le traitement de la douleur